FDA advisory committees meet January 26 on Salk HIV-1 immunogen.
D016915:AIDS Vaccines / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration; D015164:Vaccines, Inactivated / Q000627:therapeutic use
D016915:AIDS Vaccines; D015164:Vaccines, Inactivated